Esperion Therapeutics Inc. Shares Close the Week 22.4% Lower - Weekly Wrap
The company saw its shares close the week 22.4% lower than last week, with trading volume lower than its 30 day average.
Jan 11, 2022 by Kwhen Finance Editors
Esperion Therapeutics Inc. (ESPR) shares closed this week 22.4% lower than it did at the end of last week. The stock is currently down 19.4% year-to-date, down 87.0% over the past 12 months, and down 70.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%.
Trading Activity
- Shares traded as high as $5.28 and as low as $3.90 this week.
- Shares closed 89.8% below its 52-week high and 3.3% above its 52-week low.
- Trading volume this week was 1.3% higher than the 10-day average and 13.4% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
- The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Esperion Therapeutics Inc. | -2.9 | -19.4 | -87.0 | ||
| Dow Jones Industrial Average | -0.4 | -0.7 | 18.0 | -2.3 | 22.9 |
| S&P 500 Index | -0.1 | -2.0 | 23.7 | -3.6 | 27.3 |
| Health Care | 0.9 | -5.2 | 13.2 | -6.3 | 20.4 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 112.0%
- The company's stock price performance over the past 12 months lags the peer average by 1022.8%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Esperion Therapeutics Inc. | ESPR | 0 | -19.4 | -87.0 | ||
| Peer Avg | N/A | 161.0 | -9.2 | -7.8 | -3.7 | 18.1 |
| Pfizer Inc. | PFE | 16.3 | -5.6 | 55.9 | -9.9 | 71.4 |
| Regeneron Pharmaceuticals, Inc. | REGN | 9.1 | -4.4 | 21.1 | -12.1 | 36.9 |
| Biomarin Pharmaceutical Inc. - Registered Shares | BMRN | 973.4 | -4.5 | -6.1 | ||
| Ultragenyx Pharmaceutical Inc. | RARE | -14.0 | -13.1 | -51.5 | ||
| Amicus Therapeutics Inc | FOLD | -11.0 | -18.2 | -59.2 | ||
| Lexicon Pharmaceuticals Inc | LXRX | -7.9 | -9.1 | -6.8 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: